Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common painkiller boost emergency contraception? new trial tests combo pill

NCT ID NCT06727734

Disease control Sponsor: The University of Hong Kong Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a combination of levonorgestrel (a hormone) and piroxicam (an anti-inflammatory drug) works better than the standard emergency contraceptive ulipristal acetate. About 980 women will take a single dose of either the combo or the standard pill, then be followed for up to 6 weeks to see who becomes pregnant. The goal is to find a more effective way to prevent pregnancy after unprotected sex.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Levonorgestrel and piroxicam combination
What this could lead to
If successful, this could offer a more effective emergency contraception option than the current standard ulipristal acetate.
What could go wrong
This is a Phase 3 trial, but results may not show a clear advantage. Side effects like menstrual changes or drug interactions are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 980 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2025

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. women aged 18-45 years; 2. requesting an oral EC within 120 hours of a single or the first act of unprotected intercourse in the current menstrual cycle; 3. available for follow-up over the next 6 weeks. Exclusion Criteria: 1. post-abortion or postpartum and period have not yet returned, 2. being on the following drugs currently: anticoagulants, cyclosporine, tacrolimus, corticosteroids, lithium, serotonin reuptake inhibitors (SSRIs), quinolones 3. having unprotected intercourse in this cycle more than 120 hours before attending the clinic, 4. being found pregnant at the time of presentation, 5. breastfeeding, 6. having been sterilized (or partner having been sterilized) or having intrauterine contraceptive device in-situ, 7. uncertain about the date of the last menstrual period, 8. having used a hormonal contraceptive (including EC), progestogen-containing medication or NSAID in the recent one week, 9. having history of asthma, urticaria or other allergic reactions to piroxicam, aspirin or other NSAIDs, 10. having history of ischaemic heart disease, heart failure, hypertension, cerebrovascular disease or kidney failure requiring dialysis 11. having history of peptic ulcer disease and/or gastrointestinal bleeding.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Contraception are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contraception

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The Family Planning Association of Hong Kong

    RECRUITING

    Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.